AGP Executive Report
Last update: 8 hours agoCardiac Devices: Abbott won U.S. FDA approval and European CE marking for its UltiSynq defibrillation lead; it was implanted successfully in 202 of 205 trial patients. Prostate Cancer: J&J is leading an investment in Francis Medical to advance its water-vapor ablation device toward FDA review for localized prostate cancer. Diabetes Research: IIT Kanpur researchers found pancreatic immune cells can suppress insulin release within minutes; the pathway was also active in human tissue, offering a potential direction for future drug research. Medicine Access: A global report found access plans cover 69% of major drugmakers’ late-stage pipeline, but millions in low- and middle-income countries still struggle to obtain essential medicines. Stroke Prevention: The FDA approved asundexian, a first-in-class drug to reduce the risk of another stroke after ischemic stroke or TIA. Vaccine Update: Moderna’s RSV vaccine showed strong protection against severe illness in adults aged 50 and older.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
